Literature DB >> 9429124

Lamotrigine: pharmacokinetics.

W R Garnett1.   

Abstract

The pharmacokinetics of lamotrigine have been studied in single and multiple dose studies in animals, normal volunteers, and patients with epilepsy. Lamotrigine exhibits first-order linear pharmacokinetics. Lamotrigine is well absorbed with bioavailability approaching 100%. The absorption is unaffected by food and there is no first-pass metabolism. The volume of distribution is between 1.25 and 1.47 L/kg and protein binding is about 55%. The half-life of lamotrigine is between 24.1 and 35 hours in drug naive adults but may be altered by enzyme inducing and inhibiting drugs. Clinical trials demonstrated no evidence of autoinduction or saturable metabolism. Younger children (0.17 to 5 years) eliminate lamotrigine faster than older children (5 to 10 years). Children may be more prone to enzyme induction than adults.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9429124     DOI: 10.1177/0883073897012001041

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  18 in total

1.  Lamotrigine pharmacokinetic evaluation in epileptic patients submitted to VEEG monitoring.

Authors:  A M Almeida; A C Falcão; F Sales; I Baldeiras; M J Rocha; M M Caramona
Journal:  Eur J Clin Pharmacol       Date:  2006-07-27       Impact factor: 2.953

Review 2.  Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction.

Authors:  M Strolin Benedetti; R Whomsley; E Baltes; F Tonner
Journal:  Eur J Clin Pharmacol       Date:  2005-11-24       Impact factor: 2.953

3.  Interaction between paracetamol and lamotrigine: new insights from the FDA Adverse Event Reporting System (FAERS) database.

Authors:  Carla Carnovale; Giulia Mosini; Michele Gringeri; Vera Battini; Faizan Mazhar; Marco Pozzi; Emilio Clementi; Sonia Radice
Journal:  Eur J Clin Pharmacol       Date:  2019-06-14       Impact factor: 2.953

4.  Authors' Reply to Standing et al.: "Effect of Age-Related Factors on the Pharmacokinetics of Lamotrigine and Potential Implications for Maintenance Dose Optimisation in Future Clinical Trials".

Authors:  Sven C van Dijkman; Nico C B de Jager; Willem M Rauwé; Meindert Danhof; Oscar Della Pasqua
Journal:  Clin Pharmacokinet       Date:  2018-11       Impact factor: 6.447

5.  A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug-Drug Interactions.

Authors:  Todd M Conner; Ronald C Reed; Tao Zhang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-06       Impact factor: 2.441

Review 6.  Pharmacokinetics and therapeutic drug monitoring of newer antiepileptic drugs during pregnancy and the puerperium.

Authors:  Torbjörn Tomson; Dina Battino
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Spotlight on lamotrigine in bipolar disorder.

Authors:  David R Goldsmith; Antona J Wagstaff; Tim Ibbotson; Caroline M Perry
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

8.  Pharmacokinetics of lamotrigine and its metabolite N-2-glucuronide: Influence of polymorphism of UDP-glucuronosyltransferases and drug transporters.

Authors:  Daniela Milosheska; Bogdan Lorber; Tomaž Vovk; Matej Kastelic; Vita Dolžan; Iztok Grabnar
Journal:  Br J Clin Pharmacol       Date:  2016-05-29       Impact factor: 4.335

Review 9.  Lamotrigine: a review of its use in bipolar disorder.

Authors:  David R Goldsmith; Antona J Wagstaff; Tim Ibbotson; Caroline M Perry
Journal:  Drugs       Date:  2003       Impact factor: 9.546

10.  Population pharmacokinetics of lamotrigine in Chinese children with epilepsy.

Authors:  Da-ke He; Li Wang; Jiong Qin; Shen Zhang; Wei Lu; Ling Li; Jian-ming Zhang; Wei-qun Bao; Xiao-qing Song; Hai-tao Liu
Journal:  Acta Pharmacol Sin       Date:  2012-10-29       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.